1.Camoquin, a 4-aminoquinoline compound, was administered in a single dose to 160 patients with falciparum malaria and 165 patients with vivax malaria. There were four unselected groups, and the dosage in terms of Camoquin base was either 0.4 Gm., 0.6 Gm., 0.8 Gm., or 1.0 Gm.
2.For all falciparum cases, the average number of hours for attainment of sustained normal temperature was 17.1 and the average number of hours for parasitemia disappearance was 29.2. Those patients who received 1.0 Gm. Camoquin did a little better than the other dosage groups (13.2 hours for normal temperature and 26.3 hours for disappearance of parasitemia).
3.For all vivax cases, the average number of hours for attainment of sustained normal temperature was 15.8 and the average number of hours for parasitemia disappearance was 26.4. There was no appreciable difference in the response of the four dosage groups.
4.Generally, those patients who received only 0.4 Gm. of Camoquin (38 falciparum and 37 vivax) did as well as those receiving the higher dosages. However, the only two relapses or failures observed were in two individuals with falciparum malaria who had been given only 0.4 Gm. of the drug.
5.Camoquin is a relatively non-toxic drug.
6.Camoquin deserves more widespread use in malarious areas throughout the world, and should be particularly valuable in rural locations and/or when hospitalization is not feasible.